About three in 10 adults report not taking their medicines as prescribed at some point in the past year because of the cost, according to a survey by KFF.
Affordability of prescription drugs is a key issue for Americans, according to a survey by KFF. This is especially true for those who are taking four or more prescriptions; 37% of these respondents say they have difficulty affording their prescriptions, compared with 18% who currently take three or fewer prescription medications. Those with household incomes of than the $40,000 are more likely to report difficulty affording medications.
Additionally, 31% adults report not taking their medicines as prescribed at some point in the past year because of the cost. This includes 21% who report they have not filled a prescription or took an over-the counter drug instead, and 12% who say they have cut pills in half or skipped a dose because of the cost. (See Figure below.)
Among those surveyed by KFF, 73% support regulations that would address drug prices, including limiting the price of prescription drugs. Among Democrats, 82% support limiting prices; among Republicans, 67% support limiting prices.
Source: KFF
FDA Advisory Committee Supports Donanemab in Alzheimer’s Disease
June 11th 2024Committee members, however, also said more data are needed on donanemab to treat patients in underrepresented patient groups, including Latin American and African American patients and special populations such as Down syndrome.
Read More
FDA Sets Review Date for Tagrisso for Specific Lung Cancer Mutations
June 10th 2024Tagrisso, which is already available to treat patients with non-small cell lung cancer and EGFR mutations, is being reviewed by the FDA for patients with this cancer and exon 19 deletions or exon 21 mutations.
Read More
ICER Releases List of Drugs for Fair Access Review
June 7th 2024Included in this review will be 11 drugs that ICER assessed for cost-effectiveness in 2022. New this year is an assessment for consumer accessibility of drugs, including the burdens of prior authorization and patient cost-sharing measures.
Read More
Updated: FDA Committee, Concerned about Bias, Votes No on Psychedelic in PTSD
June 5th 2024Patients with PTSD in the clinical trials of midomafetamine were able to guess whether they received treatment or placebo. Regulators and advisory committee members said this could have impacted efficacy results. FDA’s decision is expected by Aug. 11, 2024.
Read More